A Multicenter, Randomised, Double Blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER - Goal of Oxidised Ldl and Activated Macrophage Inhibition by Exposure to a Recombinant Antibody).

Trial Profile

A Multicenter, Randomised, Double Blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER - Goal of Oxidised Ldl and Activated Macrophage Inhibition by Exposure to a Recombinant Antibody).

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2016

At a glance

  • Drugs Orticumab (Primary) ; HMG-CoA reductase inhibitors
  • Indications Atherosclerosis; Cardiovascular disorders; Inflammation
  • Focus Therapeutic Use
  • Acronyms GLACIER
  • Sponsors Genentech
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jul 2012 Primary endpoint 'Atherosclerotic-plaque-parameters' has not been met.
    • 02 Mar 2012 Status changed from recruiting to active, no longer recruiting, according to a BioInvent International AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top